FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1196-1199 March 16, 2006 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: We, the non-Merck authors of the VIGOR study,¹ welcome the opportunity to respond to your recent expression of concern² regarding the VIGOR study. No Merck employee or representative was involved in the drafting of this response. Our evaluation leads us to conclude that our original article followed appropriate clinical trial principles and does not require a correction. Three basic assertions were made in the expression of concern, and we would like to address these assertions point by point.

Point 1: Three additional myocardial infarctions were not included in the VIGOR paper and at least two of the . . . [Full Text of this Article]

This article has been cited by other articles:

• Ross, J. S., Hill, K. P., Egilman, D. S., Krumholz, H. M. (2008). Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation. JAMA 299: 1800-1812 [Abstract] [Full Text]  
• Criner, G. J. (2007). Framing the Forum: Medical Ethics in Large-Scale, Interventional Respiratory Clinical Trials. Proc Am Thorac Soc 4: 171-175 [Abstract] [Full Text]  
• Zhang, J., Ding, E. L., Song, Y. (2006). Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials. JAMA 296: 1619-1632 [Abstract] [Full Text]  
• Curfman, G. D., Morrissey, S., Drazen, J. M. (2006). Expression of Concern Reaffirmed. NEJM 354: 1193-1193 [Full Text]